Health
EpicGenetics agrees to stop selling two questionable blood tests
A diagnostics company has agreed to stop selling two questionable blood tests as part of a settlement with a consumer watchdog that accused the company of using “false and misleading advertising” to promote its products.
EpicGenetics not only claimed that one of its blood tests could definitively diagnose fibromyalgia, according to the October 2023 lawsuit from the Center for Science in the Public Interest; the company had also invented a disease wholesaler to justify the use of another product, and had dangled non-existent treatment trials as an enticement to patients.
EpicGenetics, founder and CEO Bruce Gillis, and his other companies continue to deny any wrongdoing, but they have agreed to stop marketing and selling these two tests to limit the claims they make about other products. and to pay $158,000 in CSPI’s legal fees. , according to the settlement, which went into effect on July 30.
This article is exclusive to STAT+ subscribers
Unlock this article – plus in-depth analysis, newsletters, premium events and access to networking platforms.
Do you already have an account? Login
Do you already have an account? Login
View all subscriptions
Get unlimited access to award-winning journalism and exclusive events.
Subscribe
